TSE:GUD Knight Therapeutics (GUD) Stock Forecast, Price & News C$4.42 -0.01 (-0.23%) (As of 09/25/2023 ET) Add Compare Share Share Today's RangeC$4.38▼C$4.4350-Day RangeC$4.38▼C$4.9352-Week RangeC$4.28▼C$5.60Volume32,890 shsAverage Volume97,723 shsMarket CapitalizationC$471.92 millionP/E RatioN/ADividend YieldN/APrice TargetC$6.25 ProfileProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesHeadlinesSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesHeadlinesSocial Media Knight Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside41.4% UpsideC$6.25 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring SharesC$115,738 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.14 out of 5 stars 3.3 Analyst's Opinion Consensus RatingKnight Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of C$6.25, Knight Therapeutics has a forecasted upside of 41.4% from its current price of C$4.42.Amount of Analyst CoverageKnight Therapeutics has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for GUD. Previous Next 0.0 Dividend Strength Dividend YieldKnight Therapeutics does not currently pay a dividend.Dividend GrowthKnight Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GUD. Previous Next 2.8 News and Social Media Coverage News SentimentKnight Therapeutics has a news sentiment score of 2.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Knight Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought C$115,738.00 in company stock and sold C$0.00 in company stock.Percentage Held by Insiders42.84% of the stock of Knight Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 14.24% of the stock of Knight Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Knight Therapeutics is -31.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Knight Therapeutics is -31.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioDue to a projected decrease in earnings for Knight Therapeutics, their PEG ratio cannot be calculated.Price to Book Value per Share RatioKnight Therapeutics has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Knight Therapeutics (TSE:GUD) StockKnight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.Read More GUD Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GUD Stock News HeadlinesSeptember 14, 2023 | theglobeandmail.comClosing Bell: Knight Therapeutics Inc flat on Thursday (GUD)August 12, 2023 | markets.businessinsider.comKnight Therapeutics (KHTRF) Receives a Buy from RBC CapitalSeptember 26, 2023 | Chaikin Analytics (Ad)Get Your Cash Out of U.S. Banks ImmediatelyMan who predicted 2023 bank run warns a historic financial reset is coming. Get out of cash and into a new vehicle 50 years in the making. Click here to learn more.August 10, 2023 | theglobeandmail.comTrading For This Specialty Pharma Company is up Following Second Quarter ResultsAugust 10, 2023 | finance.yahoo.comKnight Therapeutics Reports Second Quarter 2023 ResultsAugust 3, 2023 | finance.yahoo.comNotice of Knight Therapeutics' Second Quarter 2023 Results Conference CallJune 7, 2023 | theglobeandmail.comClosing Bell: Knight Therapeutics Inc up on Tuesday (GUD)June 2, 2023 | finance.yahoo.comKnight to Present at the Jefferies 2023 Healthcare Conference in New York CitySeptember 26, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 31, 2023 | theglobeandmail.comClosing Bell: Knight Therapeutics Inc down on Wednesday (GUD)May 26, 2023 | finance.yahoo.comSamira Sakhia Bought 12% More Shares In Knight TherapeuticsMay 26, 2023 | finance.yahoo.comSamira Sakhia Bought 12% More Shares In Knight Therapeutics \May 23, 2023 | finance.yahoo.comShareholders in Knight Therapeutics (TSE:GUD) are in the red if they invested five years agoMay 8, 2023 | theglobeandmail.comClosing Bell: Knight Therapeutics Inc down on Monday (GUD)May 4, 2023 | finance.yahoo.comNotice of Knight Therapeutics' First Quarter 2023 Results Conference CallApril 28, 2023 | theglobeandmail.comClosing Bell: Knight Therapeutics Inc down on Friday (GUD)April 18, 2023 | finance.yahoo.comKnight to Present at the 2023 Bloom Burton & Co. Healthcare Investor ConferenceApril 10, 2023 | theglobeandmail.comClosing Bell: Knight Therapeutics Inc up on Monday (GUD)March 25, 2023 | marketwatch.comKnight Therapeutics Inc. ranks on The Globe and Mail's fourth-annual Women Lead Here benchmark of executive gender diversityMarch 23, 2023 | finance.yahoo.comKnight Therapeutics Reports Fourth Quarter and Year-End 2022 ResultsFebruary 28, 2023 | benzinga.comKnight Therapeutics Stock (OTC:KHTRF), Quotes and News SummaryJanuary 27, 2023 | nypost.comSpielberg: ‘Dark Knight’ should’ve been Oscars’ first Best Picture blockbusterJanuary 18, 2023 | msn.comWayne Knight Claims Seinfeld 'Obliterated' His Film CareerNovember 8, 2022 | finance.yahoo.comBullish insiders bet CA$2.9m on Knight Therapeutics Inc. (TSE:GUD)October 11, 2022 | finance.yahoo.comKnight Therapeutics Inc. (TSE:GUD) most popular amongst individual investors who own 57%, insiders hold 20%September 23, 2022 | finance.yahoo.comKnight Therapeutics Inc. places No. 22 on The Globe and Mail's fourth-annual ranking of Canada's Top Growing CompaniesSeptember 1, 2022 | reuters.comKnight Therapeutics IncSee More Headlines Receive GUD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GUD Company Calendar Last Earnings8/10/2023Today9/25/2023Next Earnings (Estimated)11/09/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE Industry Drug Manufacturers—Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolTSE:GUD CUSIPN/A CIKN/A Webwww.gud-knight.com Phone514-484-4483FaxN/AEmployees698Year FoundedN/APrice Target and Rating Average Stock Price ForecastC$6.25 High Stock Price ForecastC$6.50 Low Stock Price ForecastC$6.00 Forecasted Upside/Downside+41.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)C($0.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth-1013.5Net IncomeC$-15,690,000.00 Net Margins-4.81% Pretax MarginN/A Return on Equity-1.92% Return on Assets-0.84% Debt Debt-to-Equity Ratio9.81 Current Ratio3.16 Quick Ratio1.79 Sales & Book Value Annual SalesC$326.44 million Price / Sales1.45 Cash FlowC$1.15 per share Price / Cash Flow3.85 Book ValueC$7.53 per share Price / Book0.59Miscellaneous Outstanding Shares106,770,000Free FloatN/AMarket CapC$471.92 million OptionableNot Optionable Beta0.48 10 Best Stocks to Own in 2023Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Jonathan Ross Goodman B.A. (Age 54)BA, L.L.B., LLB, M.B.A., MBA, Exec. Chairman Comp: $250.94kMs. Samira Sakhia BCom (Age 55)CA, CPA, MBA, Pres, CEO & Director Comp: $674.28kMr. Arvind UtchanahChief Financial OfficerMs. Amal Khouri B.Sc.M.B.A., Chief Bus. OfficerMr. Jeff MartensGlobal VP of CommercialMr. Stephani SaverioVP of Bus. Devel.Mr. Leopoldo BosanoVice-Pres of Manufacturing & OperationsMs. Monica PercarioGlobal VP of Scientific AffairsMr. Henrique DiasGlobal Director of MarketingMs. Susan Caroline EmblemGlobal VP of HRMore ExecutivesKey CompetitorsAurora CannabisTSE:ACBOrganigramTSE:OGIHLS TherapeuticsTSE:HLSCronos GroupTSE:CRONExtendicareTSE:EXEView All CompetitorsInsidersSime ArmoyanBought 26,400 shares on 9/15/2023Total: C$115,737.60 ($4.38/share)View All Insider Transactions GUD Stock - Frequently Asked Questions Should I buy or sell Knight Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GUD shares. View GUD analyst ratings or view top-rated stocks. What is Knight Therapeutics' stock price forecast for 2023? 2 Wall Street research analysts have issued 1-year price objectives for Knight Therapeutics' stock. Their GUD share price forecasts range from C$6.00 to C$6.50. On average, they predict the company's share price to reach C$6.25 in the next twelve months. This suggests a possible upside of 41.4% from the stock's current price. View analysts price targets for GUD or view top-rated stocks among Wall Street analysts. How have GUD shares performed in 2023? Knight Therapeutics' stock was trading at C$5.18 at the beginning of the year. Since then, GUD shares have decreased by 14.7% and is now trading at C$4.42. View the best growth stocks for 2023 here. When is Knight Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our GUD earnings forecast. How were Knight Therapeutics' earnings last quarter? Knight Therapeutics Inc. (TSE:GUD) issued its earnings results on Thursday, August, 10th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by $0.01. The business had revenue of $89.91 million for the quarter, compared to analysts' expectations of $80.15 million. Knight Therapeutics had a negative net margin of 4.81% and a negative trailing twelve-month return on equity of 1.92%. What other stocks do shareholders of Knight Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Knight Therapeutics investors own include Constellation Software (CSU), Bombardier, Inc. Class B (BBD.B), Brookfield Infrastructure Partners (BIP.UN), Enbridge (ENB), Spin Master (TOY), Alimentation Couche-Tard (ATD.B), Chemtrade Logistics Income Fund (CHE.UN), Canadian National Railway (CNR), Dollarama (DOL) and Extendicare (EXE). What is Knight Therapeutics' stock symbol? Knight Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "GUD." How do I buy shares of Knight Therapeutics? Shares of GUD stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What is Knight Therapeutics' stock price today? One share of GUD stock can currently be purchased for approximately C$4.42. How much money does Knight Therapeutics make? Knight Therapeutics (TSE:GUD) has a market capitalization of C$471.92 million and generates C$326.44 million in revenue each year. The company earns C$-15,690,000.00 in net income (profit) each year or C($0.14) on an earnings per share basis. How many employees does Knight Therapeutics have? The company employs 698 workers across the globe. How can I contact Knight Therapeutics? Knight Therapeutics' mailing address is 3400 de Maisonneuve Boulevard West, Suite 1055, Montreal, QC H3Z 3B8, Canada. The official website for the company is www.gud-knight.com. The company can be reached via phone at 514-484-4483. This page (TSE:GUD) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.